These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27622603)

  • 1. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
    Allen PB; Gordon LI
    Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint inhibitors in Hodgkin's lymphoma.
    Jezeršek Novaković B
    Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in classical Hodgkin's lymphoma.
    Maly J; Alinari L
    Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
    Cheah CY; Fowler NH; Neelapu SS
    Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting immune checkpoints in lymphoma.
    Ansell SM
    Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
    Dada R
    Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.
    Baues C; Semrau R; Gaipl US; Bröckelmann PJ; Rosenbrock J; Engert A; Marnitz S
    Strahlenther Onkol; 2017 Feb; 193(2):95-99. PubMed ID: 27704149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
    Jelinek T; Paiva B; Hajek R
    Front Immunol; 2018; 9():2431. PubMed ID: 30505301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
    Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
    Bröckelmann PJ; Engert A
    Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.